Literature DB >> 18575197

Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006.

Gugu Maphalala1, Velephi Okello, Sibongile Mndzebele, Prudence Gwebu, Nomsa Mulima, Sandile Dlamini, Bonisile Nhlabatsi, Themba Ginindza, Yohannes Ghebrenegus, Augustine Ntilivamunda, Fabian Mwanyumba, Johanna Ledwaba, Visva Pillay, Diane E Bennett.   

Abstract

BACKGROUND: In resource-limited settings where antiretroviral treatment (ART) is being scaled-up, the World Health Organization (WHO) recommends the surveillance of transmitted HIV drug resistance (HIVDR). We used the WHO's HIVDR threshold survey method to assess transmitted HIVDR in three antenatal clinic (ANC) sites along the corridor between the two most populous cities in Swaziland, where ART was introduced in 2003.
METHODS: From July-August 2006, remnant sera were aliquoted from HIV serosurvey specimens collected from 70 primagravidas <25 years old attending ANC during the national HIV serosurvey. Genotyping was performed at the National Institute for Communicable Diseases, South Africa. Transmitted resistance was defined by the WHO's surveillance list of mutations. HIVDR prevalence was categorized using the WHO's threshold survey binomial sequential sampling method.
RESULTS: Among the 70 eligible specimens, 61 were sequenced--60 (98%) were identified as subtype C and one as subtype B. No major nucleoside or non-nucleoside reverse transcriptase inhibitor mutations occurred among the first 34 consecutive specimens, which supported a transmitted resistance categorization to these drug classes as <5%. One protease inhibitor mutation, M461, was seen among the first 44 specimens, supporting a categorization of PI resistance as <5%.
CONCLUSION: Our survey indicates that prevalence of transmitted HIVDR among recently infected pregnant women along the Manzini-Mbabane corridor is low (<5%). Surveys will be carried out in this area biannually and may be extended to other areas. Surveys for transmitted resistance make up one element among a spectrum of activities to assess and support minimization of HIVDR.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18575197

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  17 in total

1.  Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso.

Authors:  Antoine Somda; Lassana Sangare; Monique Soro; Saydou Yameogo; Babou Bazie; Françoise Bigirimana; Silvia Bertagnolio; Martine Peeters; Fatima Mouacha; Ana Maria Rivera; Michael R Jordan; Marie-Joseph Sanou
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  Poor performance of the determine HIV-1/2 Ag/Ab combo fourth-generation rapid test for detection of acute infections in a National Household Survey in Swaziland.

Authors:  Yen T Duong; Yvonne Mavengere; Hetal Patel; Carole Moore; Julius Manjengwa; Dumile Sibandze; Christopher Rasberry; Charmaine Mlambo; Zhi Li; Lynda Emel; Naomi Bock; Jan Moore; Rejoice Nkambule; Jessica Justman; Jason Reed; George Bicego; Dennis L Ellenberger; John N Nkengasong; Bharat S Parekh
Journal:  J Clin Microbiol       Date:  2014-08-13       Impact factor: 5.948

3.  Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.

Authors:  Praphan Phanuphak; Sunee Sirivichayakul; Awachana Jiamsakul; Somnuek Sungkanuparph; Nagalingeswaran Kumarasamy; Man Po Lee; Thira Sirisanthana; Pacharee Kantipong; Christopher Lee; Adeeba Kamarulzaman; Mahiran Mustafa; Rossana Ditangco; Tuti Merati; Winai Ratanasuwan; Thida Singtoroj; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2014-05-01       Impact factor: 3.731

Review 4.  Drug resistance surveillance in resource-poor settings: current methods and considerations for TB, HIV, and malaria.

Authors:  Bethany L Hedt; Miriam K Laufer; Ted Cohen
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

Review 5.  The global status of HIV drug resistance: clinical and public-health approaches for detection, treatment and prevention.

Authors:  Steven Y Hong; Jean B Nachega; Karen Kelley; Silvia Bertagnolio; Vincent C Marconi; Michael R Jordan
Journal:  Infect Disord Drug Targets       Date:  2011-04

6.  Transmitted drug resistance in nonsubtype B HIV-1 infection.

Authors:  Philip A Chan; Rami Kantor
Journal:  HIV Ther       Date:  2009-09-01

7.  The prevalence of transmitted drug resistance in newly diagnosed HIV-infected individuals in Croatia: the role of transmission clusters of men who have sex with men carrying the T215S surveillance drug resistance mutation.

Authors:  Ivana Grgic; Snjezana Zidovec Lepej; Maja M Lunar; Mario Poljak; Adriana Vince; Ivana Baca Vrakela; Ana Planinic; Katja Seme; Josip Begovac
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

8.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

9.  Contrasting predictors of poor antiretroviral therapy outcomes in two South African HIV programmes: a cohort study.

Authors:  Mison Dahab; Salome Charalambous; Alan S Karstaedt; Katherine L Fielding; Robin Hamilton; Lettie La Grange; Gavin J Churchyard; Alison D Grant
Journal:  BMC Public Health       Date:  2010-07-22       Impact factor: 3.295

10.  Short communication: HIV type 1 transmitted drug resistance and evidence of transmission clusters among recently infected antiretroviral-naive individuals from Ugandan fishing communities of Lake Victoria.

Authors:  Jamirah Nazziwa; Harr Freeya Njai; Nicaise Ndembi; Josephine Birungi; Fred Lyagoba; Asiki Gershim; Jessica Nakiyingi-Miiro; Leslie Nielsen; Juliet Mpendo; Annet Nanvubya; Jan Debont; Heiner Grosskurth; Anatoli Kamali; Janet Seeley; Pontiano Kaleebu
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05       Impact factor: 2.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.